WO2003020879A3 - Cells and methods for propagating adenoviral vectors - Google Patents

Cells and methods for propagating adenoviral vectors Download PDF

Info

Publication number
WO2003020879A3
WO2003020879A3 PCT/US2002/024051 US0224051W WO03020879A3 WO 2003020879 A3 WO2003020879 A3 WO 2003020879A3 US 0224051 W US0224051 W US 0224051W WO 03020879 A3 WO03020879 A3 WO 03020879A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
methods
adenoviral vectors
replication
propagating
Prior art date
Application number
PCT/US2002/024051
Other languages
French (fr)
Other versions
WO2003020879A2 (en
Inventor
Douglas E Brough
Jason G D Gall
Joseph T Bruder
Imre Kovesdi
Original Assignee
Genvec Inc
Douglas E Brough
Jason G D Gall
Joseph T Bruder
Imre Kovesdi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/911,020 external-priority patent/US20030040100A1/en
Priority claimed from US09/911,011 external-priority patent/US6677156B2/en
Priority claimed from US09/910,828 external-priority patent/US6682929B2/en
Application filed by Genvec Inc, Douglas E Brough, Jason G D Gall, Joseph T Bruder, Imre Kovesdi filed Critical Genvec Inc
Priority to AU2002327380A priority Critical patent/AU2002327380A1/en
Publication of WO2003020879A2 publication Critical patent/WO2003020879A2/en
Publication of WO2003020879A3 publication Critical patent/WO2003020879A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Abstract

The invention pertains to cells for the propagation of adenoviral vectors. The invention further provides methods of propagating a replication-deficient adenoviral vector which comprises providing an inventive cell, introducing a replication-deficient adenoviral vector into the inventive cell, and maintaining the cell to propagate the replication-deficient adenoviral vector.
PCT/US2002/024051 2001-07-23 2002-07-22 Cells and methods for propagating adenoviral vectors WO2003020879A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002327380A AU2002327380A1 (en) 2001-07-23 2002-07-22 Cells and methods for propagating adenoviral vectors

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US30721201P 2001-07-23 2001-07-23
US09/911,020 2001-07-23
US09/911,011 2001-07-23
US09/911,020 US20030040100A1 (en) 2001-07-23 2001-07-23 Cell for the propagation of adenoviral vectors
US60/307,212 2001-07-23
US09/910,828 2001-07-23
US09/911,011 US6677156B2 (en) 2001-07-23 2001-07-23 Non-adenoviral gene product-based complementing cells for adenoviral vectors
US09/910,828 US6682929B2 (en) 2001-07-23 2001-07-23 Adenovector complementing cells

Publications (2)

Publication Number Publication Date
WO2003020879A2 WO2003020879A2 (en) 2003-03-13
WO2003020879A3 true WO2003020879A3 (en) 2003-10-30

Family

ID=27501930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/024051 WO2003020879A2 (en) 2001-07-23 2002-07-22 Cells and methods for propagating adenoviral vectors

Country Status (2)

Country Link
AU (1) AU2002327380A1 (en)
WO (1) WO2003020879A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1972958B (en) 2004-04-12 2013-01-23 美国政府卫生与公共服务部 Method of using adenoviral vectors to induce an immune response
BRPI0615400A2 (en) 2005-08-31 2011-05-17 Genvec Inc adenoviral vector-based malaria vaccines
BRPI0618441B8 (en) 2005-11-10 2021-07-27 Genvec Inc adenoviral vector
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057248A2 (en) 2009-11-09 2011-05-12 Genvec, Inc. Simian adenovirus and methods of use
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
ES2887335T3 (en) 2010-03-17 2021-12-22 Univ Cornell Vaccine against drugs of abuse based on altered adenovirus
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
EP2654786B1 (en) 2010-12-20 2019-02-20 GenVec, Inc. Adenoviral vector-based dengue fever vaccine
CN103987726B (en) 2011-10-05 2017-10-03 金维克有限公司 Monkey (gorilla) adenovirus or adenovirus vector and its application method
WO2013052811A2 (en) 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vectors and methods of use
WO2013052859A2 (en) 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
IN2014DN03005A (en) 2011-10-05 2015-05-08 Genvec Inc
US20150157700A1 (en) 2012-02-02 2015-06-11 GanVec, Inc. Adenoviral vector-based malaria vaccine
WO2013181128A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Modified serotype 28 adenoviral vectors
EP2855511B1 (en) 2012-05-29 2019-07-24 GenVec, Inc. Herpes simplex virus vaccine
CA3038968A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
KR20200128703A (en) 2018-03-06 2020-11-16 프레시전 인코포레이티드 Hepatitis B vaccine and uses thereof
JP2023517011A (en) 2020-03-05 2023-04-21 ネオティーエックス セラピューティクス リミテッド Methods and compositions for treating cancer using immune cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BROUGH ET AL.: "A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4", JOURNAL OF VIROLOGY, vol. 70, no. 9, September 1996 (1996-09-01), pages 6497 - 6501, XP002923470 *
HORVATH ET AL.: "Complementation of adenovirus early region 1a and 2a mutants by epstein-barr virus immortalized lymphoblastoid cell lines", VIROLOGY, vol. 184, 1991, pages 141 - 148, XP002963061 *
TEVETHIA ET AL.: "Participation of two human cytomegalovirus immediate early gene regions in transcriptional activation of adenovirus promoters", VIROLOGY, vol. 161, 1987, pages 276 - 285, XP001106578 *

Also Published As

Publication number Publication date
AU2002327380A1 (en) 2003-03-18
WO2003020879A2 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
WO2003020879A3 (en) Cells and methods for propagating adenoviral vectors
IL214623A0 (en) Method for providing cell population from umbilical cord blood or placenta
AU2001291656A1 (en) Gene silencing vector
AU2001265154A1 (en) Method and composition for targeting an adenoviral vector
WO2003095636A3 (en) Activation induced deaminase (aid)
WO2002077264A3 (en) Arrayed transfection method and uses related thereto
AU5095699A (en) Liver stem cell
WO2000047720A3 (en) Pancreatic progenitor cells, methods and uses related thereto
AU2002248136A1 (en) Cloning vectors and vector components
WO2002068627A3 (en) Vector constucts
AU2001257532A1 (en) Adenoviral vectors for tumor specific gene expression and uses thereof
WO2003050260A3 (en) Streptavidin expressed gene fusions and methods of use thereof
WO2002068635A3 (en) Methods of inhibiting expression of a target gene in mammalian cells
WO2004022586A3 (en) Tubulysin biosynthesis gene
WO2004099422A3 (en) Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
AU2001280576A1 (en) Tissue-specific self-inactivating gene therapy vector
WO2003052083A3 (en) Methods for the generation of proliferating and differentiating cell lines
WO2007134325A3 (en) Methods and compositions for protein production using adenoviral vectors
WO2002084451A3 (en) Vector processor architecture and methods performed therein
AU2003256681A1 (en) Low loss waveguide launch
AU2002337892A1 (en) Vectors for expressing multiple transgenes
AU2002218019A1 (en) Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
EP1546178A4 (en) Adenoviral va1 pol iii expression system for rna expression
AU2002225011A1 (en) Method for improving the water balance of fuel cells
AU2002306539A1 (en) Minimal plasmid vectors that provide for persistent and high level gene expression and methods for using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP